MedTrace Logo

N-Acetyl Cysteine Plus Behavioral Therapy for Nicotine Dependent Pathological Gamblers

NCT00967005 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2023-03-21

Study results available
· View outcomes & findings →

Summary

The objective of this application is to examine whether, given its mechanism of action, the dietary supplement, N-acetyl cysteine (NAC) will reduce both tobacco use and pathological gamblers (PG) symptoms in nicotine dependent pathological gamblers.

Conditions

  • Gambling
  • Tobacco Use Disorder

Interventions

DRUG

N Acetyl Cysteine

N-Acetyl Cysteine, 1200mg-3000mg each day for 24-weeks

OTHER

Sugar Pill

placebo control

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • University of Minnesota

    collaborator OTHER

  • University of Chicago

    lead OTHER

Principal Investigators

  • Marc N Potenza, MD, PhD · Yale University

  • Jon E Grant, MD, JD, MPH · University of Minnesota

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2012-09-30
Completion
2014-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00967005 on ClinicalTrials.gov